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Abstract 
The novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is a 
major public health challenge all over the world and is the causative agent of coronavirus disease 2019 
(COVID-19). Since December2019 the outbreak of COVID-19 has become a major epidemic issue all 
over world. In this pandemic, preterm and term neonates with infected mothers are becoming more 
vulnerable each day. Although we mostly witness asymptomatic neonates, getting symptomatic may 
not be a rarity in the future. After entrance of COVID-19 into the body it could affect the balance of 
microbiota combination which can result in microbiota dysbiosis and eventually leads to immune 
imbalance. Intrauterine microbiome dysbiosis in COVID-19 positive mothers and transmission of 
lipopolysaccharide (LPS) may restructure the environment of the developing fetus with possible 
short/long-term impact on the individual’s health and disease. Therefore, assessing the changes in 
microbiome of neonates from infected mothers via exploring meconium could be valuable. It is also 
logical to measure LPS level and balanced its levels by using prebiotics and probiotics as a supplemental 
therapeutic procedure to prevent medical challenges in future. The aim of this essay is to review the 
potential conception that detection of COVID-19 and the meconium microbiota and LPS quantity could 
be used as a source of prognostic information about the COVID-19 severity in the fetus of pregnant 
women with COVID-19. 
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1. COVID-19 outbreak  
The novel coronavirus, severe acute respiratory 
syndrome coronavirus 2 (SARS CoV-2) termed is a 
great public health challenge, and is the causative 
agent of coronavirus disease 2019 (COVID-19). Since 
December 2019 the outbreak of COVID-19 has 
become a major epidemic issue all over world [1, 2]. In 
this pandemic, when the world is in constant battle to 
stop the spread of infection and prevent mortality, 
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preterm and term neonates with infected mothers are 
becoming more vulnerable each day. Although we 
mostly witness asymptomatic neonates [3], getting 
symptomatic may not be a rarity in the future.  
 
2. COVID-19, microbial translocation and 
microbial toxins during pregnancy 
No proof of vertical transition of COVID-19 has 
been found yet [4], affirming placenta as an efficient 
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obstacle even in case of severe infection. But some 
research declared that the virus is a potential risk 
factor for enforcing intense placental disruption 
independently of vertical transition [5]. Shanes et al. 
analyzed the placentas of 16 women affected 
intensively with COVID-19, the placentas indicated 
fetomaternal vascular poor perfusion and intervillous 
thrombus (IVT). This study proposes a malformed 
maternal diffusion reflecting a systemic inflammatory 
or hypercoagulable condition affecting placenta’s 
function which could be associated with adverse 
perinatal outcomes [6].  
After entrance of COVID-19 into the body it could 
affect the balance of microbiota combination which 
can result in microbiota dysbiosis and eventually leads 
to immune imbalance [7]. It is possible to observe 
simultaneous penetration of microbial toxic 
metabolites like bacterial lipopolysaccharide (LPS), 
into intrauterine space. This potent cytokine storm 
inducer then might lead to immune imbalances in 
neonates, which are predictable. 
It is demonstrated that COVID-19 spike protein 
attaches to bacterial LPS and increases inflammatory 
activations [8]. N proteins of SARS-CoV-2 and Middle 
East respiratory syndrome coronavirus (MERS-CoV) 
exasperate LPS causing  pneumonia through 
triggering  MASP-2  activity [9]. The presence and 
transmission of LPS to the fetus and pregnancy fluids 
and their potency to induce lung inflammatory 
diseases has also been demonstrated in previous 
studies [10, 11]. Based on these findings, we consider 
that it may be possible to measure the amount of LPS 
in the body as a prognostic marker of COVID-19 in 
pregnant mother or newborn baby. 
In order to measure toxic metabolites like 
bacterial LPS and detection of COVID-19, a safe and 
reliable test is highly required besides neonatal 
nasopharyngeal swabs (which could be highly 
invasive), assessing amniotic fluid, cord blood which 
are mostly negative. The hypothesis of this essay is to 
review the value of meconium microbiota and LPS 
quantification as an origin of prognostic data toward 
the severity of COVID-19 in the neonate of women 
with positive COVID-19 (Figure 1).  
The inutero bacterial situation could be 
manifested by microbial mixture of meconium. The 
presence of bacteria in the embryo’s bowel is 
recognized as a basis for microbial provocation and 
can supply an essential signal for a balanced immune 
function [12]. Microbiome combination is a biologic 
material, which could be highly recommended as a 
clinical diagnostic routine test for diagnosis and follow 





Figure 1. Routes of microbial and LPS translocation. Illustration present probable known pathways for 
translocation of mother microbiota and microbial products to fetus. Different population of bacteria, virus or 
microbial toxins could translocate and colonize in fetus meconium and make it a rich sample for analysis  
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3. Microbial translocation: mechanism, 
immunity, physiology of emerging diseases 
and probable probiotic supportive role 
More than 30 years ago, for the first time the 
existence of some kinds of microbes in the amnion in 
the absence of any disruption was announced [13]. 
There are several hypotheses for the transplacental 
transition of bacteria and their products into utero. 
The most probable theory is bacterial transition from 
the mother’s bowel to blood circulation and then to the 
organs including uterine [14]. During pregnancy, 
maternal’s small intestinal epithelial cells (dendritic 
cells and micro fold cells) can actively pass through the 
epithelium of intestine, pick up the bacteria or their 
genome and deliver them to the amniotic liquid [15-
17]. This presumption is established by empiric studies 
in pregnant mice fed Enterococcus faecium by mouth, 
this bacterium was detected in the blood of umbilical 
cord, amniotic fluid, meconium and placenta [18]. 
Mother's microbiome could affect infant's immune 
system by means of its bacterial products. Microbiota 
produce multiple substances that can interfere with 
different biological actions, immune modulating and 
energy producing functions [19]. The immune system 
recognizes microbial metabolites and pathogen-
associated molecular patterns (PAMPs), the sensation 
of these molecules can cause direct influence on 
immune process [20-22]. Hence, compensating 
microbiota imbalance could be beneficial for 
immunity of fetus for both short and long term, one 
easy and safe method for this aim is using prebiotic 
and probiotic products. It is indicated that using 
probiotics is an effective and promising approach to 
stop intestinal problems in neonates [23, 24]. 
Maternal immune factors have a significant role in 
bacterial invasive actions into the amniotic fluid; this 
invasion can boost an inflammation cascade 
eventually leading in preterm labor [25]. 
Hypothetically, swallowing amniotic fluid by fetus can 
make it gut susceptible to microbes and their 
metabolites translocation and permeability, which 
may be a significant contributor to early immune 
progress in neonates. It is demonstrated that, memory 
CD4+ and CD8+ T cells could be recognized at the end 
of third month in embryo’s intestines [26]. Memory 
CD4+ T cells in embryo’s gut have been proved to 
collaborate with antigen presenting cells (APCs) and 
leads to generation of interferon gamma (IFN-γ), 
interleukin-2 (IL-2) or tumor necrosis factor-α (TNF-
α), assisting intestine’s expansion [27, 28]. Ultimately, 
it is presumed that early fetus access to microbial  
metabolites and LPS may have a considerable 
influence on infant’s immune system in future and 
make them more susceptible to different diseases like 
diabetes mellitus, allergy [29], autism [30], obesity 
[31], and neurodegenerative diseases like Alzheimer’s 
diseases [32]. On the other hand, many studies have 
shown that exposure to LPS can cause symptoms of 
neurological diseases such as Alzheimer's, which can 
be a late symptom in COVID-19 patients. This may be 
a bridge between bacterial LPS that can be released as 
a result of antibiotic treatments and the death of 
Gram-negative bacteria in the body and contribute to 
the formation and deterioration of cytokine storms 
[33, 34]. 
It is possible that mother’s viral infections result in 
the gut microbiota change during pregnancy with 
enduring outcomes for the neonates. It is 
demonstrated that fetal brain growth can be affected 
by improper gut flora of mother which can cause long-
lasting neurological consequences. Several studies on 
mice indicated that maternal viral infection can cause 
reduction in intestinal barrier integrity in the children, 
as a consequence considerable changes in intestinal 
microbial combination and microbial metabolism 
were observed leading to autism-like behavior and 
neuropathology. For instance, it was demonstrated 
that giving Bacteroides fragilis to the mice in their 
pregnancy enhanced the gut microbiota combination 
and gut penetrance in the neonates and decreased the 
occurrence of autism [14, 17, 18]. 
Multiple studies mentioned that the anal swabs 
from the individuals with COVID-19 were positive (35, 
[35, 36], and the COVID-19 could have been separated 
from the fecal specimen of COVID-19 positive patients 
by various medical teams [37]. In a case report study 
in China, the anal swabs of a three-month-old girl was 
still positive nearly a month after the onset of the 
illness even when she had no symptom and 14 days 
after her oropharyngeal swabs were negative her anal 
swabs were still positive [38]. 
 
4. Comprehensive conclusion 
Intrauterine microbiome dysbiosis in COVID-19 
positive mothers may restructure the condition of the 
embryo by viable short-term and long-term influence 
on the human’s health state. Therefore, assessing the 
changes in microbiome of neonates from infected 
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mothers via exploring meconium could be valuable. It 
is also logical to measure LPS level and balance it by 
using prebiotics, probiotics or symbiotic as a 
supplemental therapeutic procedure to prevent 
medical challenges in future. So far, there has been no 
study conducted to test physiological relation of 
maternal microbiota toxic metabolites like bacterial 
LPS in COVID-19 positive mothers and neonate’s 
meconium. We suggest to analyze meconium’s LPS 
levels and Gram-negative microbiota as a noninvasive, 
reliable and potential package test beside other virus 
detection methods of COVID-19 in infants with 
COVID-19 positive mothers. It could equip us with 
better strategies to keep newborns safe. Because levels 
of mentioned microbiome and their products like LPS, 
might act as a clock bomb during probable cytokine 
storm formation.    
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